Stephens Investment Management Group LLC Purchases 43,680 Shares of Medpace Holdings, Inc. $MEDP

Stephens Investment Management Group LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 36.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 162,797 shares of the company’s stock after acquiring an additional 43,680 shares during the quarter. Medpace makes up about 1.1% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 25th largest holding. Stephens Investment Management Group LLC owned 0.57% of Medpace worth $78,173,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the fourth quarter worth approximately $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the fourth quarter valued at approximately $30,000. Quarry LP bought a new stake in Medpace in the third quarter valued at approximately $35,000. Finally, Bayban acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MEDP. Barclays reduced their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird decreased their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. BMO Capital Markets dropped their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Finally, Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $557.60 on Friday. The firm has a market cap of $15.93 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.83 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92. The business’s 50 day moving average is $453.88 and its 200-day moving average is $496.63.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.